We found that the combination treatment group had a higher percentage of tumor‐infiltrating CD8+ T cells and tumor‐infiltrating tetramer+CD8+ T cells (tumor‐infiltrating antigen‐specific CD8+ T cells) than the control group (Figure 4D). The gene discussed is CD8A; the disease is neoplasm.